- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
LIC shareholding in Dr Reddy's crosses 5 percent mark
This translates into an investment of Rs 1,556.41 crore to buy over 33.3 lakh shares of the pharma company.
New Delhi: LIC has raised its stake in pharma major Dr Reddy's Laboratories to over 5 percent by way of open market stock purchases during September 2021 to June this year, at an estimated cost of Rs 1,556 crore.Corporation's shareholding in Dr Reddy's Laboratories has increased from 60,64,345 to 93,96,801 equity shares, or from 3.644 per cent to 5.646 per cent of the paid-up capital of the...
New Delhi: LIC has raised its stake in pharma major Dr Reddy's Laboratories to over 5 percent by way of open market stock purchases during September 2021 to June this year, at an estimated cost of Rs 1,556 crore.
Corporation's shareholding in Dr Reddy's Laboratories has increased from 60,64,345 to 93,96,801 equity shares, or from 3.644 per cent to 5.646 per cent of the paid-up capital of the said company, LIC said in a regulatory filing on Thursday.
The life insurer said it bought shares through open market purchase from September 3, 2021 to June 15, 2022 at an average cost of Rs 4,670.46.
This translates into an investment of Rs 1,556.41 crore to buy over 33.3 lakh shares of the pharma company.
Dr Reddy's is engaged in manufacturing of Active Pharamceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars and differentiated formulations.
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751